The stock of Moleculin Biotech Inc (MBRX) has seen a 20.10% increase in the past week, with a -15.69% drop in the past month, and a -49.23% decrease in the past quarter. The volatility ratio for the week is 13.13%, and the volatility levels for the past 30 days are at 11.88% for MBRX. The simple moving average for the past 20 days is -0.93% for MBRX’s stock, with a -57.27% simple moving average for the past 200 days.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Moreover, the 36-month beta value for MBRX is 1.66. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MBRX is 14.01M and currently, short sellers hold a 4.08% of that float. On April 17, 2025, MBRX’s average trading volume was 5.65M shares.
MBRX) stock’s latest price update
Moleculin Biotech Inc (NASDAQ: MBRX)’s stock price has soared by 8.25 in relation to previous closing price of 0.85. Nevertheless, the company has seen a gain of 20.10% in its stock price over the last five trading days. zacks.com reported 2025-04-01 that Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Analysts’ Opinion of MBRX
Oppenheimer, on the other hand, stated in their research note that they expect to see MBRX reach a price target of $14. The rating they have provided for MBRX stocks is “Outperform” according to the report published on July 18th, 2022.
MBRX Trading at -14.23% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.20% of loss for the given period.
Volatility was left at 11.88%, however, over the last 30 days, the volatility rate increased by 13.13%, as shares sank -11.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.28% lower at present.
During the last 5 trading sessions, MBRX rose by +19.35%, which changed the moving average for the period of 200-days by -73.89% in comparison to the 20-day moving average, which settled at $0.9279. In addition, Moleculin Biotech Inc saw -45.94% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBRX
The total capital return value is set at -2.3. Equity return is now at value -135.80, with -78.93 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -49.92.
Currently, EBITDA for the company is -26.52 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
To wrap up, the performance of Moleculin Biotech Inc (MBRX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
